Boston Breast Cancer Care to Shift Sites This October
Breast cancer patients will see changes to where they receive oncology and surgical care starting on October 19.
Updated on Oct. 15, 2026 in Cancer
Live Poll
Do you believe hospital system mergers in your community typically lead to better patient care?
Starting Monday, October 19, 2026, Dana-Farber Cancer Institute will shift its breast oncology services from Brigham and Women's Hospital to Beth Israel Deaconess Medical Center. This move marks the beginning of a new collaborative care model for Boston patients requiring specialized breast cancer treatment.
Why it matters
This transition changes how patients access breast oncology care and surgical procedures in Boston, marking a significant step toward a new standalone cancer hospital. It shifts the local landscape of care delivery as institutions prepare for a long-term restructuring of major cancer services in the region.
The transition represents a shift in institutional capacity, characterized by the staffing of a nine-surgeon division at Beth Israel Deaconess Medical Center. While this move centralizes services, the long-term impact on surgical wait times remains under investigation.
The players
Dana-Farber Cancer Institute
A comprehensive cancer treatment and research center that is transitioning its breast oncology services.
Beth Israel Deaconess Medical Center
A Boston teaching hospital that is becoming the primary surgical site for Dana-Farber breast cancer patients.
Dr. Elizabeth Mittendorf
A surgical oncologist who joined Beth Israel Deaconess Medical Center in 2025.
Brigham and Women's Hospital
A major teaching hospital that is currently ending its long-term partnership with Dana-Farber.
Mass General Brigham
A health system currently investing $400 million to create a competing cancer institute.
The details
Under this new model, Dana-Farber will manage outpatient oncology care, while surgical breast cancer procedures will move to Beth Israel Deaconess Medical Center. Surgeons at Beth Israel Deaconess will work in close coordination with Dana-Farber departments, including radiation, pathology, and reconstructive surgery. This integration aims to align multidisciplinary teams under a unified care pathway for complex oncology cases.
Timeline
October 19, 2026: Transition of breast oncology services begins.
2028: The partnership between Dana-Farber and Brigham and Women's Hospital ends.
2031: A new 300-bed cancer hospital is slated to open.
Health Landscape
This transition is a major step toward the construction of a new 300-bed, $1.68 billion cancer hospital scheduled to open in 2031. It follows a shifting pattern of local oncology care as institutions consolidate to compete with other major investments in the Massachusetts health sector.
Patients currently receiving care for breast cancer should confirm their upcoming appointments and surgical locations with their care team. If you have questions about how these location changes impact your continuity of care, bring them up during your next conversation with your physician.
The takeaway
The shifting of specialized breast cancer surgeries to Beth Israel Deaconess reflects an ongoing restructuring of cancer care in the Boston area. Patients should keep an open dialogue with their oncology team to understand how these institutional changes affect their specific treatment schedules.
Further reading
Patients can find more information on navigating local oncology care at the Cancer section.
Source note: This article includes information reported by The Boston Globe.
Live Poll
Do you believe hospital system mergers in your community typically lead to better patient care?
